make better heart decisions with hart tests
AI-Powered to Manage Your Heart with Confidence
Novel Artificial Intelligence (AI)-Driven Cardiac Blood Tests
Introducing the HART Cardiovascular Blood Tests
Patient Use
order test kit
VIEW clinIcal evidence
info guide for physicians
info guide for patients
- NT-proBNP- associated with myocardial (heart) stress
- Kidney Injury Molecule-1 (KIM-1)- associated with cardiorenal dysfunction and injury
- Osteopontin (OPN)- associated with calcification and plaque formation
- Tissue Inhibitor of Metalloproteinases-1 (TIMP-1)- associated with plaque rupture potential and left ventricular enlargement and dysfunction
"The Future”: the only marketed prognostic blood test for 1-year risk of heart attack (MI), stroke or cardiac death (MACE or major adverse cardiovascular events). Yielding an accuracy of 86%, HART CVE™ assesses four clinically significant blood proteins in a machine learning (AI) algorithm to calculate a patient- specific risk score. Proteins include:
HART CVE™ provides clinical use in wellness testing, monitoring patients with known and unknown cardiovascular disease, patients with a history of typical or atypical cardiovascular symptoms, and patients with one or more cardiac risk factors, e.g. diabetes, obesity, smokers, peripheral artery disease (PAD), family history of heart disease. Published in AJC and Biomarkers in Medicine.
order test kit
VIEW clinIcal evidence
info guide for physicians
info guide for patients
HART CADhs™ provides clinical use in baselining and monitoring patients with known and unknown cardiovascular disease, patients with a history of typical or atypical cardiovascular symptoms, and patients with high cardiovascular risk, e.g., diabetes, obesity, smokers, peripheral artery disease (PAD), family history of heart disease. Published in JAHA August 2020.
In 2022, HART CVE™ and HART CADhs™ were each awarded with proprietary PLA/CPT codes by the AMA (American Medical Association).
- hsTroponin- associated with myocardial ischemia and injury
- Kidney Injury Molecule-1 (KIM-1)- associated with cardiorenal dysfunction and injury
- Adiponectin- associated with glucose and fatty acid metabolism
“The Here and Now”: diagnostic blood test for obstructive coronary artery disease. Yielding an accuracy of 86%, HART CADhs™ assesses three clinically significant blood proteins and three clinical variables (age, sex, history of coronary intervention) in a machine learning (AI) algorithm to calculate a patient- specific risk score of obstructive coronary artery disease. Proteins include:
Research Use
Using Prevencio's HART Tests for Medical Research
order test kit
VIEW clinIcal evidence
info guide for physicians
- NT-proBNP- associated with myocardial (heart) stress
- Kidney Injury Molecule-1 (KIM-1)- associated with cardiorenal dysfunction and injury
- Osteopontin (OPN)- associated with calcification and plaque formation
- Tissue Inhibitor of Metalloproteinases-1 (TIMP-1)- associated with plaque rupture potential and left ventricular enlargement and dysfunction
"The Future”: the only marketed prognostic blood test for 1-year risk of heart attack (MI), stroke or cardiac death (MACE or major adverse cardiovascular events). Yielding an accuracy of 86%, HART CVE™ assesses four clinically significant blood proteins in a machine learning (AI) algorithm to calculate a patient- specific risk score. Proteins include:
HART CVE™ provides clinical use in wellness testing, monitoring patients with known and unknown cardiovascular disease, patients with a history of typical or atypical cardiovascular symptoms, and patients with one or more cardiac risk factors, e.g. diabetes, obesity, smokers, peripheral artery disease (PAD), family history of heart disease. Published in AJC and Biomarkers in Medicine.
order test kit
VIEW CLINICAL EVIDENCE
info guide for physicians
HART CADhs™ provides clinical use in baselining and monitoring patients with known and unknown cardiovascular disease, patients with a history of typical or atypical cardiovascular symptoms, and patients with high cardiovascular risk, e.g., diabetes, obesity, smokers, peripheral artery disease (PAD), family history of heart disease. Published in JAHA August 2020.
In 2022, HART CVE™ and HART CADhs™ were each awarded with proprietary PLA/CPT codes by the AMA (American Medical Association).
- hsTroponin- associated with myocardial ischemia and injury
- Kidney Injury Molecule-1 (KIM-1)- associated with cardiorenal dysfunction and injury
- Adiponectin- associated with glucose and fatty acid metabolism
“The Here and Now”: diagnostic blood test for obstructive coronary artery disease. Yielding an accuracy of 86%, HART CADhs™ assesses three clinically significant blood proteins and three clinical variables (age, sex, history of coronary intervention) in a machine learning (AI) algorithm to calculate a patient- specific risk score of obstructive coronary artery disease. Proteins include:
order test kit
VIEW CLINICAL EVIDENCE
- Assess pre-drug/post-drug effects on peripheral artery disease.
- Significantly more accurate (AUC = 0.85) than Standard-of-Care Stress Tests (AUC = 0.52) for diagnosing Coronary Artery Disease.
Blood test for obstructive peripheral artery disease diagnosis.
- For commercialization, the HART PAD panel was optimized to consist of one clinical variable (history of hypertension) and three biomarkers (Kidney Injury Molecule-1, osteopontin, and adiponectin).
order test kit
VIEW CLINICAL EVIDENCE
Blood test for aortic valve stenosis.
- Predicts with 98% accuracy to exclude severe AS.
- Diagnose and monitor progression of aortic valvular stenosis.
order test kit
VIEW CLINICAL EVIDENCE
- Assess amputation risk in a mixed group of diabetics and non-diabetics with an overall accuracy measurement of 87% (AUC = 0.87).
Blood test for risk of amputation.
order test kit
VIEW CLINICAL EVIDENCE
Blood test for the risk of acute kidney injury.
- Has a negative predictive value of 98% and an overall accuracy measurement of 82% (AUC = 0.82).
Actionable, Personalized Blood Test Results to Help You Make Informed Health Decisions
order test kit
- HART Tests can be used in phase IV Drug/Device trials on pre-/post-drug or device comparisons to confirm clinical efficacy of treatment.
- HART Tests can aid in understanding the diagnosis, progression, regression, prediction, or outcome of treatment and bring personalized medicine into clinical studies.
- HART Tests can be used for "Early" Drug/Device Development to Identify and Screen target populations.
- HART Tests can assess potential for anticipated and unanticipated effects/toxicity.
- HART Tests can be used as a guide for assessing the tolerance of ascending doses of a drug.
